Healthcare · Pharmaceuticals & Biotechnology
QVM read Mixed signals Quality Moderate, Valuation Expensive, Momentum Bearish
Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.
Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.
PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.
Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.
Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.
Ranks #25 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.
| Date | Client | Deal | Action | Quantity | Price | Exchange |
|---|---|---|---|---|---|---|
| 20 Feb 2025 | GRAVITON RESEARCH CAPITAL LLP | Bulk | Sell | 6,856,958 | 219.8800 | NSE |
| 20 Feb 2025 | GRAVITON RESEARCH CAPITAL LLP | Bulk | Buy | 6,856,958 | 219.7000 | NSE |
| 31 Oct 2023 | EAST BRIDGE CAPITAL MASTER FUND LIMITED | Block | Sell | 33,643,099 | 102.8000 | BSE |
| 31 Oct 2023 | EAST BRIDGE CAPITAL MASTER FUND I LIMITED | Block | Buy | 33,643,099 | 102.8000 | BSE |
| 31 Oct 2023 | EAST BRIDGE CAPITAL MASTER FUND I LIMITED | Bulk | Buy | 33,643,099 | 102.8000 | BSE |
| 31 Oct 2023 | EAST BRIDGE CAPITAL MASTER FUND LIMITED | Bulk | Sell | 33,643,099 | 102.8000 | BSE |
| 3 Nov 2022 | ISHARES CORE MSCI EMERGING MARKETS ETF | Block | Buy | 4,050,700 | 166.9500 | BSE |
| 3 Nov 2022 | ISHARES CORE EMERGING MARKETS MAURITIUS CO | Block | Sell | 4,050,700 | 166.9500 | BSE |
| 1 Nov 2022 | BLACKROCK ADVISORS LLC A/C THE MASTER TRUST BANK OF JAPAN L | Bulk | Sell | 14,066,087 | 158.8800 | NSE |
| 1 Nov 2022 | BLACKROCK ADVISORS LLC A/C THE MASTER TRUST BANK OF JAPAN L | Bulk | Buy | 310,097 | 158.4900 | NSE |
| Ex-date | Subject | Per share (₹) | Record date |
|---|---|---|---|
| 16 Jul 2025 | Dividend - Re 0.14 Per Share | 0.1400 | 16 Jul 2025 |
| 12 Jul 2024 | Dividend - Rs 0.11 Per Share | 0.1100 | 12 Jul 2024 |
Bonuses, splits, buybacks and other events. Dividends are listed separately above.
| Ex-date | Type | Subject |
|---|---|---|
| 2 Aug 2023 | RIGHTS | Rights 5:46 @ Premium Rs 71/- |
Quarterly results, AGMs, buybacks and other board-approved business.
| Date | Purpose | Results |
|---|---|---|
| 29 Jul 2026 | Financial Results | Yes |
| 28 Apr 2026 | Financial Results | Yes |
| 28 Jan 2026 | Financial Results | Yes |
| 5 Nov 2025 | Financial Results | Yes |
| 28 Jul 2025 | Financial Results | Yes |
Exchange disclosures (NSE and BSE), most recent first.
| Date | Category | Announcement |
|---|---|---|
| 1 Oct 2026 | Company Update | Piramal Pharma Ltd - 543635 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Expiry And Non-Renewal Of Commercial Arrangement With Bayer Pharmaceuticals Private Limited |
| 1 Oct 2026 | Company Update | Piramal Pharma Ltd - 543635 - Clarification On News Item Which Appeared In The 'Www.Thehindubusinessline.Com' Dated September 30, 2026 Captioned 'Ontario Contributes $1.7 Million Investment To Advance Life Sciences Innovation At Piramal Pharma'S Aurora Facility.' |
| 1 Oct 2026 | Updates | Piramal Pharma Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of the SEBI (Listing Obligations and DisclosureRequirements) Regulations, 2015 - Expiry and Non-Renewal of CommercialArrangement with Bayer Pharmaceuticals Private Limited'. |
| 1 Oct 2026 | News Verification | The Exchange has sought clarification from Piramal Pharma Limited with respect to recent news item captioned Ontario Contributes $1.7 Million Investment to Advance Life Sciences Innovation at Piramal Pharmas Aurora Facility.. The response from the Company is attached. |
| 30 Sep 2026 | Company Update | Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Change in Management |
| 30 Sep 2026 | Company Update | Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Change in Management |
| 30 Sep 2026 | Company Update | Piramal Pharma Ltd - 543635 - Clarification sought from Piramal Pharma Ltd |
| 30 Sep 2026 | Change in Management | Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India(Listing Obligations and Disclosure Requirements) Regulations, 2015 Appointment of Senior Management Personnel |
| 30 Sep 2026 | Change in Management | Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India(Listing Obligations and Disclosure Requirements) Regulations, 2015 Changes in Senior Management Personnel |
| 30 Sep 2026 | News Verification | The Exchange has sought clarification from Piramal Pharma Limited with respect to recent news item captioned Ontario Contributes $1.7 Million Investment to Advance Life Sciences Innovation at Piramal Pharmas Aurora Facility.. The response from the Company is awaited. |
Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.
Data unavailable.
Board of directors and corporate information →
Single-stock futures and a real listed options chain available for this stock -- OI buildup, PCR, Max Pain and Greeks are all on the full F&O page.
Part of: NIFTY 500, NIFTY 500, NIFTY PHARMA, NIFTY PHARMA
The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.
The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.
The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.
No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.
